Erwan Bezard, PhD
INSERM Research Director at Institute of Neurodegenerative Diseases, CNRS UMR 5293, University Victor Segalen
Location: Bordeaux, France
Erwan Bezard, INSERM Research Director, has authored or co-authored over 230 professional publications in the field of neurobiology, most of which are on Parkinson's disease and related disorders. Listed in the top one percent of the most cited neuroscientists (H factor= 64 - Google Scholar), he is known for his work on the compensatory mechanisms that mask the progression Parkinson's disease and on the pathophysiology of levodopa-induced dyskinesia, the intimate mechanisms of cell death in Parkinson's disease, the modelling of disease progression and the development of new strategies to alleviate symptoms and/or to slow disease progression.
Bezard is the director of a CNRS research unit located in Bordeaux, the Institute of Neurodegenerative Diseases, which features pre-clinical and clinical researchers working toward development of therapeutic solutions. He is also a visiting professor at the China Academy of Medical Sciences in Beijing, where he has set up and manages a non-human primate facility dedicated to movement disorders.
He has served or currently sits on the boards of international organizations such as The Michael J. Fox Foundation and Parkinson's UK. He is associate editor of Neurobiology of Disease and of Synapse, two leading journals in the field. He serves on the editorial boards of several other neurobiology journals. Besides consulting for several drug companies in the field of movement disorders, he is a non-executive director of Plenitudes Sarl (France) and Motac Neuroscience (UK).
- Neuroprotective Effects of NFE2L1 in Parkinson's Models (2018)
- Neuroprotective Effects of Endosulfine-alpha in Parkinson's Disease (2017)
- Neuroprotective Effects of Endosulfine-alpha in PD (2016)
- Evaluation of the Oligomer Modulator anle138b in a Seeding-based Model of Parkinsons Disease (2014)
- Deciphering the Role of Histone Deacetylase in Levodopa-Induced Dyskinesia (2013)
- Mu Opioid Receptor Target for Levodopa-Induced Dyskinesia: Stop or Continue? (MOR4LID) (2013)
- Prion-like Dissemination of Synuclein Pathology: A Non-human Study (2013)
- 5-Hydroxytryptophan and Eltoprazine for the Treatment of Levodopa-Induced Dyskinesia (2013)
- Combined Therapy with Amantadine and Fenobam for Levodopa-induced Dyskinesia (2012)
- Pharmacological Targeting of the 5-HT1, A2A and NMDA Receptors: An Integrative Approach to Dyskinesia (2012)
- Targeting Dramatically Activated Astrocytic Networks for Managing LID: a Target Validation Program (2011)
- Simvastatin for the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease (2008)
- Validation of metabotropic glutamate-receptor type 5 as a target for the treatment of L-DOPA-induced dyskinesia in a macaque model of Parkinsonīs disease (2007)
- Functional Inhibition of RasGRF1 in the MPTP-lesioned NHP Model for Treating Levodopa-induced Dyskinesia (2007)
- Lentivirally-Delivered GRK2 and GRK6 for Decreasing Severity of Levodopa-induced Dyskinesia (2006)
- Multi-single Unit Electrophysiological Characterization of Dyskinesia Induced by Dopamimetic Drugs (2003)